Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 509 Shares

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 509 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $40.04, for a total transaction of $20,380.36. Following the completion of the sale, the insider directly owned 34,360 shares of the company’s stock, valued at approximately $1,375,774.40. This represents a 1.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Castle Biosciences Trading Down 0.4%

Shares of NASDAQ CSTL traded down $0.16 during midday trading on Friday, hitting $39.44. 357,875 shares of the company traded hands, compared to its average volume of 454,994. Castle Biosciences, Inc. has a 12-month low of $14.59 and a 12-month high of $40.61. The firm has a market cap of $1.15 billion, a P/E ratio of -87.64 and a beta of 1.14. The stock has a 50-day moving average price of $32.49 and a 200 day moving average price of $24.44. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.31 and a current ratio of 6.47.

Castle Biosciences (NASDAQ:CSTL) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.32. Castle Biosciences had a positive return on equity of 1.73% and a negative net margin of 3.56%.The business had revenue of $80.55 million for the quarter, compared to analysts’ expectations of $71.06 million. As a group, analysts expect that Castle Biosciences, Inc. will post 0.44 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on CSTL shares. Canaccord Genuity Group reiterated a “buy” rating and issued a $37.00 price objective on shares of Castle Biosciences in a report on Tuesday, September 9th. Weiss Ratings reiterated a “sell (d)” rating on shares of Castle Biosciences in a research note on Monday. Robert W. Baird lifted their price target on shares of Castle Biosciences from $39.00 to $41.00 and gave the company an “outperform” rating in a research report on Tuesday, November 4th. BTIG Research upped their price objective on shares of Castle Biosciences from $38.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Finally, Zacks Research raised shares of Castle Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Castle Biosciences currently has a consensus rating of “Moderate Buy” and an average price target of $39.14.

Institutional Investors Weigh In On Castle Biosciences

A number of institutional investors have recently made changes to their positions in the company. Farther Finance Advisors LLC increased its position in shares of Castle Biosciences by 139,100.0% during the third quarter. Farther Finance Advisors LLC now owns 1,392 shares of the company’s stock valued at $32,000 after acquiring an additional 1,391 shares in the last quarter. State of Alaska Department of Revenue purchased a new stake in Castle Biosciences during the 3rd quarter valued at $35,000. CWM LLC increased its holdings in shares of Castle Biosciences by 80.6% in the 3rd quarter. CWM LLC now owns 1,911 shares of the company’s stock worth $44,000 after purchasing an additional 853 shares in the last quarter. Jones Financial Companies Lllp raised its stake in shares of Castle Biosciences by 10,592.0% in the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock worth $54,000 after purchasing an additional 2,648 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its stake in shares of Castle Biosciences by 63.7% in the third quarter. Russell Investments Group Ltd. now owns 2,508 shares of the company’s stock worth $57,000 after purchasing an additional 976 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.